Ionis Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Ionis Pharmaceuticals, Inc. (IONS) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $88.00 thousand for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2017-08-09
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-06-30 was $88.00K.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-03-31 was -$102.00K.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2016-06-30 was -$10.74M.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2016-03-31 was -$2.55M, a 134.61% decline year-over-year.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2016 was -$16.79M.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2015 was -$53.31M, a 385.59% decline from fiscal 2014.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2014 was $18.67M, a 117.06% increase from fiscal 2013.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2013 was $8.60M, a 35.09% decline from fiscal 2012.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2017-06-30 | $88.00K 10-Q · filed 2017-08-09 | -$14.00K 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | -$102.00K 10-Q · filed 2017-05-09 | |||||
| 2016-12-31 | -$16.79M 10-K · filed 2017-03-01 | |||||
| 2016-06-30 | -$10.74M 10-Q · filed 2017-08-09 | -$13.29M 10-Q · filed 2017-08-09 | ||||
| 2016-03-31 | -$2.55M 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | -$53.31M 10-K · filed 2017-03-01 | |||||
| 2015-03-31 | $7.37M 10-Q · filed 2015-05-05 | $30.22M derived: sum of 2 quarters · filed 2017-03-01 | $22.39M derived: sum of 3 quarters · filed 2017-03-01 | $18.11M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2014-12-31 | $22.85M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $15.03M derived: sum of 2 quarters · filed 2017-03-01 | $10.75M derived: sum of 3 quarters · filed 2017-03-01 | $18.67M 10-K · filed 2017-03-01 | ||
| 2014-09-30 | -$7.83M 10-Q · filed 2014-11-07 | -$12.11M derived: sum of 2 quarters · filed 2014-11-07 | -$4.19M 10-Q · filed 2014-11-07 | -$12.13M derived: sum of 4 quarters · filed 2015-05-05 | ||
| 2014-06-30 | -$4.28M 10-Q · filed 2014-08-04 | $3.64M 10-Q · filed 2014-08-04 | -$4.30M derived: sum of 3 quarters · filed 2015-05-05 | -$2.27M derived: sum of 4 quarters · filed 2015-05-05 | ||
| 2014-03-31 | $7.92M 10-Q · filed 2015-05-05 | -$21.00K derived: sum of 2 quarters · filed 2015-05-05 | $2.01M derived: sum of 3 quarters · filed 2015-05-05 | $11.22M derived: sum of 4 quarters · filed 2015-05-05 | ||
| 2013-12-31 | -$7.94M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$5.91M derived: sum of 2 quarters · filed 2015-03-02 | $3.30M derived: sum of 3 quarters · filed 2015-03-02 | $8.60M 10-K · filed 2015-03-02 | ||
| 2013-09-30 | $2.04M 10-Q · filed 2014-11-07 | $11.24M derived: sum of 2 quarters · filed 2014-11-07 | $16.54M 10-Q · filed 2014-11-07 | $28.18M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $9.20M 10-Q · filed 2014-08-04 | $14.51M 10-Q · filed 2014-08-04 | $26.14M derived: sum of 3 quarters · filed 2015-03-02 | $26.02M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $5.30M 10-Q · filed 2014-05-06 | $16.94M derived: sum of 2 quarters · filed 2015-03-02 | $16.82M derived: sum of 3 quarters · filed 2015-03-02 | $18.03M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2012-12-31 | $11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $11.51M derived: sum of 2 quarters · filed 2015-03-02 | $12.72M derived: sum of 3 quarters · filed 2015-03-02 | $13.25M 10-K · filed 2015-03-02 | ||
| 2012-09-30 | -$122.00K 10-Q · filed 2013-11-05 | $1.09M derived: sum of 2 quarters · filed 2013-11-05 | $1.62M 10-Q · filed 2013-11-05 | |||
| 2012-06-30 | $1.21M 10-Q · filed 2013-08-06 | $3.00K 10-Q · filed 2012-08-06 | $1.74M 10-Q · filed 2013-08-06 | -$23.46M 10-Q · filed 2012-08-06 | ||
| 2012-03-31 | $528.00K 10-Q · filed 2013-05-07 | -$23.47M 10-Q · filed 2012-05-09 | ||||
| 2011-12-31 | -$1.72M 10-K · filed 2014-03-03 | |||||
| 2011-06-30 | -$18.18M 10-Q · filed 2012-08-06 | -$38.43M 10-Q · filed 2012-08-06 | ||||
| 2011-03-31 | -$20.25M 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |